The Vanguard Group 13D and 13G filings for Stoke Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 5:56 pm Unchanged |
2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK |
The Vanguard Group | 2,759,247 5.240% |
0 (Unchanged) |
Filing |
| 2024-11-04 1:56 pm Purchase |
2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK |
The Vanguard Group | 2,759,247 5.240% |
1,157,202 (+72.23%) |
Filing |
| 2023-02-09 11:32 am Sale |
2022-12-30 | 13G | Stoke Therapeutics, Inc. STOK |
The Vanguard Group | 1,602,045 4.060% |
-310,137 (-16.22%) |
Filing |
| 2022-02-10 08:37 am Purchase |
2021-12-31 | 13G | Stoke Therapeutics, Inc. STOK |
The Vanguard Group | 1,912,182 5.200% |
1,912,182 (New Position) |
Filing |